News headlines about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.503140015714 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Impax reaches $20 mln deal to end trial over generic drug’s delay (finance.yahoo.com)
- UPDATE 2-Impax reaches $20 mln deal to end trial over generic drug’s delay (feeds.reuters.com)
- Impax Laboratories (IPXL) Approve Proposed Business Combination with Amneal (streetinsider.com)
- Impax Shareholders Approve Proposed Business Combination with Amneal (finance.yahoo.com)
- Impax Laboratories (IPXL) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
Shares of Impax Laboratories stock remained flat at $$19.45 on Thursday. The stock had a trading volume of 929,978 shares, compared to its average volume of 983,906. Impax Laboratories has a 1-year low of $11.85 and a 1-year high of $25.70. The firm has a market capitalization of $1,426.97, a P/E ratio of -2.98, a PEG ratio of 0.82 and a beta of 1.01. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96.
IPXL has been the subject of several research reports. Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the company a “buy” rating in a research report on Friday, December 15th. Leerink Swann initiated coverage on Impax Laboratories in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price for the company. BidaskClub downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 16th. Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Guggenheim initiated coverage on Impax Laboratories in a research report on Tuesday, December 12th. They issued a “neutral” rating and a $18.00 target price for the company. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. Impax Laboratories currently has a consensus rating of “Hold” and a consensus price target of $20.91.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Stock Price” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/2018/03/29/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-impax-laboratories-ipxl-stock-price/1971592.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.